Merck cements its position as dominant developer of immunotherapy
Patients taking group’s lung cancer drug lived longer than those on chemotherapy
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Lung Cancer | Merck | Pharmaceuticals